Key facts
- Neway Chipscreen Biotechnology’s last known valuation is $95.3M (Jun 2023).
- It has raised $11.2M; the latest was Early Stage VC ($7.0M) in Jul 2025.
- Notable investors include Chengdu Bio-Town Investment, Essence Capital, Guosheng Capital, Sunlink Group.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Neway Chipscreen Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Neway Chipscreen Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neway Chipscreen Biotechnology
Developer of innovative biotechnologies, designed to meet the clinical demands. The company, with a focus on research and development, pioneers in creating novel therapeutic means and techniques including large molecules, nucleic acid drugs and antibody-drug conjugates (ADC), enabling patients to access treatment methods and new options with unique mechanisms of action.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2021
- Employees
- 32
- Ownership
- Privately Held (backing)
Neway Chipscreen Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neway Chipscreen Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neway Chipscreen Biotechnology in its N-PORT filings yet. We sweep new filings monthly.